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ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with few available 
treatment options. Recently, the involvement of purinergic receptor subtypes in the 
pathogenesis of different lung diseases has been demonstrated. Here we investigated 
the role of the purinergic receptor subtype P2Y2 in the context of fibrotic lung diseases.
The concentration of different nucleotides was measured in the broncho-alveolar 
lavage (BAL) fluid derived from IPF patients and animals with bleomycin-induced 
pulmonary fibrosis. In addition expression of P2Y2 receptors by different cell types 
was determined. To investigate the functional relevance of P2Y2 receptors for the 
pathogenesis of the disease the bleomycin model of pulmonary fibrosis was used. 
Finally, experiments were performed in pursuit of the involved mechanisms.
Compared to healthy individuals or vehicle treated animals, extracellular 
nucleotide levels in the BAL fluid were increased in patients with IPF and in mice 
after bleomycin administration, paralleled by a functional up-regulation of P2Y2R 
expression. Both bleomycin-induced inflammation and fibrosis were reduced in 
P2Y2R-deficient compared to wild type animals. Mechanistic studies demonstrated 
that recruitment of neutrophils into the lungs, proliferation and migration of lung 
fibroblasts as well as IL6 production are key P2Y2R mediated processes. 
Our results clearly demonstrate the involvement of P2Y2R subtypes in the 
pathogenesis of fibrotic lung diseases in humans and mice and hence support the 
development of selective P2Y2R antagonists for the treatment of IPF.
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INTRODUCTION
Although some progress has been made recently 
idiopathic pulmonary fibrosis (IPF) is still a devastating 
disease with few available treatment options, at least partly 
due to our lack of knowledge about IPF pathophysiology. 
Currently, it is supposed that the fibrotic response is driven 
by mediators secreted by abnormally activated alveolar 
epithelial cells type II after epithelial cell injury. The 
excessive deposition of collagen and other components of 
the extracellular matrix eventually results in scarring and 
destruction of the lung architecture [1–3]. 
Nucleotides such as adenosine-5′-triphosphate 
(ATP), uridine-5′-triphosphate (UTP) or uridine-5′-
diphosphate (UDP) are released into the extracellular 
space following tissue injury. Consecutively, elevated 
levels of extracellular nucleotides have been measured 
under inflammatory or hypoxic conditions [4–6]. The 
effects of extracellular nucleotides are mediated via P2 
purinergic receptors (P2Rs) which can be subdivided into 
metabotropic P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-P2Y14) 
and ionotropic P2X receptors (P2X1-P2X7) [7]. Expression 
of P2R has been shown on both immune and lung 
structural cells [5, 8]. Activation of P2Rs is associated with 
different cellular responses, including migration, release of 
cytokines or growth factors, production of reactive oxygen 
species, or apoptosis [7]. In addition, the involvement of 
specific P2R subtypes in the pathophysiology of different 
lung disorders has been shown extensively [4, 6, 8–10]. 
Recently, it has been demonstrated that ATP is released 
into the extracellular space upon bleomycin administration 
and that P2X7R-deficiency is associated with reduced 
pulmonary inflammation and fibrosis in different animal 
models [11, 12]. However, due to the above mentioned 
widespread expression of purinergic receptors the 
involvement of more than one receptor subtype is likely.
Functional expression of P2Y
2 
receptors, which are 
preferably activated by ATP or UTP, has been observed 
on different inflammatory cells including neutrophils, 
eosinophils, alveolar macrophages, and dendritic cells 
[13–16]. Previous studies demonstrated the involvement of 
this receptor subtype in allergic airway inflammation and 
chronic obstructive pulmonary disease [6, 16]. However, 
the precise role of P2Y
2
 receptors in the context of fibrotic 
lung disease has not been investigated yet.
RESULTS 
Increased extracellular ATP levels in idiopathic 
pulmonary fibrosis
Broncho-alveolar lavage (BAL) fluid obtained during 
bronchoscopy was used to measure extracellular ATP levels. 
As shown in Figure 1, ATP levels in the BAL fluid derived 
from IPF patients were significantly increased compared to 
healthy subjects (for patient characteristics see Table 1). 
Functional up-regulation of P2Y2R subtypes in 
idiopathic pulmonary fibrosis
A strong up-regulation of P2Y
2
R expression on BAL 
fluid macrophages and blood neutrophils derived from IPF 
patients compared to cells isolated from healthy individuals 
was observed (Figure 2A, 2B). ATP is known as a strong 
chemoattractant for neutrophils via P2Y
2
 receptors [17]. 
Hence, the functional relevance of increased P2Y
2
R 
expression was investigated by migration assay. The 
chemotaxis towards ATP of neutrophils isolated from IPF 
patients was stronger compared to neutrophils isolated from 
healthy individuals (Figure 2C). In line with this finding, 
ATP levels correlated with the number of leukocytes in the 
BAL fluid (r = 0.70; p = 0.03; data not shown).
Increased extracellular nucleotide levels and 
P2Y2R expression in experimental lung fibrosis
To confirm the pathophysiological relevance of 
these results in vivo we switched to the well characterized 
animal model of bleomycin-induced pulmonary fibrosis 
[18]. Extracellular ATP was significantly increased in 
the BAL fluid following bleomycin administration and 
maximal ATP concentration was observed at day 7 with a 
decline at later time points (Figure 3A), extracellular ATP 
was significantly increased in the BAL fluid following 
bleomycin administration and maximal ATP concentration 
was observed at day 7 with a decline at later time points 
(Figure 3A). Similar results were obtained when ATP 
release was visualized in vivo by ATP dependent luciferin-
induced bioluminescence from HEK293-pmeLUC cells 
(Figure 3B, 3C) [19]. In addition, BAL fluid UTP levels 
were also increased in a time-dependent manner after 
intratracheal bleomycin administration (Figure 3D).
Apart from extracellular nucleotide levels, there was 
also an up-regulation of P2Y
2
R expression in whole lung 
tissue after bleomycin instillation followed by a decline at 
later time points (Figure 4).
P2Y2R-deficiency is associated with reduced 
inflammation and fibrosis after bleomycin 
administration
We next questioned whether P2Y
2
R-deficiency 
could alter the course of fibrotic lung disease in vivo. 
Therefore, P2Y
2
R-deficient or wild type animals received 
an intratracheal injection of bleomycin or vehicle as a 
negative control at day 0. The degree of inflammation and 
fibrosis was determined at different time points (day 7, 
day 14 and day 21 after bleomycin). As shown in Figure 5, 
pulmonary inflammation was reduced in P2Y
2
R-deficient 
animals compared to wild type animals at all time points 
demonstrated by a decreased number of inflammatory cells 
in the BAL fluid (Figure 5A), decreased concentration 
of the pro-inflammatory cytokines keratinocyte-derived 
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chemokine (KC) and IL-6 (Figure 5B), and by reduced 
tissue infiltration by inflammatory cells (Figure 5D). 
Reduced fibrotic tissue remodelling was confirmed 
by reduced collagen content in the BAL fluid and on 
histological lung slides (Figure 5C). Furthermore, BAL 
fluid levels of the pro-fibrotic cytokine TGF-β (Figure 5B, 
right panel) and α1 pro-collagen expression (Figure 5C) 
were significantly lower in P2Y
2
R-deficient animals. 
P2Y2R activation is associated with multiple 
pro-inflammatory and pro-fibrotic effects
Recruitment of neutrophils into the lungs has been 
demonstrated to play a pivotal role in the pathogenesis of 
fibrotic lung disease [20]. Naïve wild type and P2Y
2
R-
deficient animals received an intratracheal injection of 
ATP and the number of inflammatory cells in the BAL 
fluid was assessed after 24 h. As shown in Figure 6A, ATP 
increased the numbers of neutrophils and macrophages in 
the lungs of wild type animals whereas no changes were 
seen in P2Y
2
R-deficient mice.
Increased migration of lung fibroblasts to the site of 
tissue injury is essential for the development of pulmonary 
fibrosis [1]. ATP induced migration of fibroblasts isolated from 
wild type but not from P2Y
2
R-deficient animals (Figure 6B).
Proliferation of lung fibroblasts is also crucial for 
the pathogenesis of pulmonary fibrosis [1]. ATP and UTP 
increased the proliferation rate of both primary murine 
and human lung fibroblasts (Figure 6C). The involvement 
of P2Y
2
R subtypes was confirmed by experiments 
with fibroblasts derived from P2Y
2
R-deficient animals 
(Figure 6C, left). 
The importance of the cytokine IL6 in the context of 
tissue remodelling has been demonstrated previously [21]. 
Stimulation of both murine and human lung fibroblasts 
with ATP or UTP resulted in a dose-dependent increase in 
IL6 production (Figure 6D). The increase in IL6 secretion 
was weaker but not absent in fibroblasts derived from 
P2Y
2
R-deficient animals (Figure 6D, middle). 
DISCUSSION
Signalling via purinergic receptors, e. g. P2Y
2
R 
subtypes, has been demonstrated to play an important 
role in the pathogenesis of various inflammatory 
disorders including bronchial asthma and COPD [7]. 
In this manuscript we investigated the involvement of 
extracellular nucleotides and the purinergic receptor P2Y
2
 
in the pathogenesis of idiopathic pulmonary fibrosis in 
humans and in the animal model of bleomycin induced 
lung fibrosis.
We found elevated ATP concentrations in the BAL 
fluid in patients suffering from IPF compared to healthy 
controls. Additionally, a time dependent increase in 
BAL fluid ATP and UTP levels, peaking at day 7 after 
bleomycin administration in mice was observed. These 
data are in contrast to a previous study claiming that BAL 
fluid ATP levels are only increased very early (day 1) after 
bleomycin application in mice [11]. A possible explanation 
might be that Riteau and co-workers used a higher dosage 
of bleomycin [11]. Nevertheless, we think that our animal 
model with a chronic increase in extracellular ATP is much 
closer to the situation in humans with chronically elevated 
BAL fluid ATP levels in IPF patients.
Figure 1: Elevated ATP levels in patients suffering from pulmonary fibrosis. ATP levels in BAL fluid obtained during 
bronchoscopy from patients with IPF (n = 22) and healthy volunteers (n = 11) were determined using a luminometric assay.  ***p < 0.001.
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Bleomycin-induced pulmonary fibrosis is known 
to be self-limiting with maximal fibrotic response 
around day 14 and a resolution of the fibrotic changes 
at later time points [18]. Hence, higher nucleotide levels 
in the extracellular space are paralleled by increased 
inflammation and fibrosis, in accordance with previous 
studies demonstrating increased extracellular ATP levels 
in inflammatory lung diseases such as bronchial asthma or 
COPD [4–6, 22]. Thereby, ATP release can occur via lytic 
and non-lytic pathways, e. g. via pannexins or connexin 
hemichannels or via exocytosis [7].
Apart from elevated extracellular nucleotide 
levels, an increased expression of P2Y
2
 receptors on 
cells derived from IPF patients and in the lung tissue of 
animals with bleomycin induced pulmonary fibrosis was 
observed. Of note in the animal model, maximal P2Y
2
R 
expression was found around day 14 when the maximal 
fibrotic response can be expected. The functional 
relevance of increased P2Y
2
 receptor expression on 
blood neutrophils was demonstrated by increased 
chemotaxis in response to ATP. In line with previous 
studies, the functional relevance was further supported 
by the finding that the ATP-induced recruitment of 
neutrophils into the lungs was highly dependent on P2Y
2
 
receptor expression [6, 17].
P2Y
2
R-deficient animals were found to be partially 
protected from bleomycin-induced pulmonary inflammation 
and fibrosis. Whereas the involvement of P2Y
2
 receptors 
in the pathogenesis of different inflammatory disorders 
(e. g. bronchial asthma, COPD or hepatitis) has been 
demonstrated previously, much less is known about the role 
of this receptor subtype in tissue remodelling and fibrosis 
[6, 16, 23–25]. The effects following P2Y
2
R-activation 
can be attributed to different mechanisms. Intrapulmonary 
ATP levels were increased in both IPF patients and animals 
after intratracheal bleomycin administration paralleled by 
increased P2Y
2
R expression. Consecutively, given the fact 
that P2Y
2
 receptors are essential for nucleotide-induced 
migration of neutrophils, elevated ATP levels in the alveolar 
space might lead to an influx of blood neutrophils into the 
lungs during the initiation and progression of fibrotic lung 
disease [6, 17]. Though the exact role of neutrophils in 
the pathophysiology of IPF is still a matter of debate, the 
release of proteolytic enzymes, reactive oxygen species, 
and profibrotic cytokines by neutrophils can contribute 
to tissue destruction and fibrosis [26–28]. In accordance, 
an increased percentage of neutrophils in the BAL fluid 
has been shown to be a predictor of early mortality in 
IPF [29]. Activation, proliferation and migration of lung 
fibroblasts eventually lead to enhanced deposition of 
Figure 2: Up-regulation of P2Y2R expression in idiopathic pulmonary fibrosis. (A) Expression of P2Y2 receptor subtypes on 
BAL cells derived from IPF patients (n = 16) and healthy individuals (n = 10) was determined by quantitative RT-PCR. (B) Neutrophils 
were isolated from whole blood of IPF patients (n = 9) and healthy individuals (n = 9) and P2Y
2
R expression was measured by quantitative 
RT-PCR. (C) Neutrophils were isolated from whole blood derived from IPF patients (n = 5) or healthy volunteers (n = 6). Migration in 
response to ATP or fMLP as a positive control was assessed using the Boyden chamber. *p < 0.05; ***p < 0.001.
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extracellular matrix components [28]. Our results clearly 
show that P2Y
2
R activation is associated with enhanced 
proliferation and migration of primary lung fibroblasts. 
Interestingly, nucleotides released upon tissue injury have 
been demonstrated to be involved in dermal wound healing 
and cardiac fibrosis via P2Y
2
R subtypes [24, 25]. Finally, 
P2Y
2
 receptor activation increased IL-6 secretion by lung 
fibroblasts, a cytokine linked with tissue remodelling and 
fibrosis apart from its well characterized role in acute 
inflammation [8, 21, 30]. 
However, it is very likely that even more 
mechanisms might be of importance in this context. 
Alveolar macrophages have been found to play a 
pivotal role in the pathogenesis of fibrotic lung diseases. 
Interestingly, P2Y
2
 receptor activation on this cell type 
has been shown to be associated with chemotaxis and 
secretion of pro-inflammatory cytokines [31–33]. 
In summary, we were able to demonstrate that 
the purinergic receptor subtype P2Y
2
R contributes to 
the pathogenesis of pulmonary fibrosis via different 
mechanisms including recruitment of neutrophils as 
well as migration, proliferation, and cytokine secretion 
of lung fibroblasts. Hence, targeting P2Y
2
R might 
be a new treatment option for idiopathic pulmonary 
fibrosis. 
MATERIALS AND METHODS
Patient materials
Broncho-alveolar lavage (BAL) fluids were 
collected from patients undergoing bronchoscopy during 
the diagnostic workup of IPF or from healthy volunteers. 
IPF was diagnosed according to published criteria [34]. 
The study was approved by the local ethics committee 
(Ethikkommission des Universitätsklinikums Freiburg). 
Animals
P2Y
2
R-deficient and wild type animals (both 
on C57BL/6 background) were bred at the University 
Freiburg. All experiments were approved by the local 
animal ethics committee (Regierungspraesidium Freiburg).
Bleomycin model of pulmonary fibrosis
Male C57BL/6 or P2Y
2
R-deficient animals were 
anaesthetized and received an i.t. injection of bleomycin 
(80 µl; 0.5mg/ml). Animals were killed at different time 
points via i. p. injection of pentobarbital (5 mg in 0.5 ml). 
BAL was performed with 3 × 1 ml of Ca2+ and Mg2+ free PBS 
Table 1: Patient characteristics
 FEV1 TLC DLCOc Age sex treatment for ILD
1 82 65 43 71 m no
2 54 56 31 49 m no
3 77 58 36 89 m no
4 55 69 N/A 84 m no
5 94.2 82 94.5 61 m no
6 72.9 76.4 61.8 73 f no
7 55 75 N/A 55 m no
8 76.5 68.3 49.7 82 m no
9 88 66 50 80 m prednisone
10 54.7 62.5 17.7 51 m no
11 39.4 35.1 9 59 m prednisone
12 86.1 75.3 N/A 86 m no
13 56.2 58.2 33.1 75 m prednisone
14 51.9 61.5 52.5 55 m prednisone
15 65.9 55.5 35.5 73 f study drug 
16 50.4 44.1 31.6 61 m Prednisone  study drug
17 43 62.5 47.8 63 m no
18 59.9 66.5 29.8 58 m prednisone
19 41.3 48.8 N/A 65 f prednisone azathioprine
20 53.1 65.7 39.7 73 f no
21 68.7 83.3 31.7 88 f no
22 33.7 37.3 17.2 59 m prednisone cyclophosphamide
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Figure 3: Elevated intrapulmonary nucleotide levels following bleomycin exposure in mice. (A) Male C57Bl/6 mice 
received an i. t. injection of BLM or vehicle on day 0. Animals were killed at the indicated time points and ATP levels were measured 
(n = 4–5 per group). (B–C) Mice received ATP-dependent luciferase-expressing HEK293 cells, followed by an i. t. injection of BLM or 
vehicle on day 0. Bioluminescence was quantified at the indicated time points (n = 3–6 per group). (D) Male C57Bl/6 mice received an i. t. 
injection of BLM or vehicle on day 0. Animals were killed at the indicated time points and UTP levels were measured (n = 4–5 per group). 
*p < 0.05; **p < 0.01; ***p < 0.001.
Figure 4: P2Y2R expression in bleomycin induced pulmonary fibrosis. Male C57Bl/6 mice received an i. t. injection of BLM or 
vehicle on day 0. Animals were killed at the indicated time points and P2R expression in lung tissue was analysed by quantitative RT-PCR 
(n = 3–5 per group). *p < 0.05.
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Figure 5: P2Y2R-deficient animals are partially protected from bleomycin induced lung injury and fibrosis. P2Y2R-
deficient or wild type mice received an i. t. injection of BLM or vehicle on day 0 and were killed 7, 14 or 21 days later. (A) Total and 
differential cell counts of the BALF were performed. (B) BALF cytokines were measured by ELISA. (C) Collagen contents were quantified 
in the BAL fluid by Sircol assay (left) and on histological lung slides (middle). α1 procollagen expression was determined by quantitative 
real time PCR (right). (D) Histological staining of lung slides (H&E). (n = 4–14 per group). *p < 0.05 compared to BLM-treated wt animals 
at the same time point.
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supplemented with 0.1 mM sodium EDTA, followed by lung 
resection and storage in OCT freezing medium. BAL cells 
were counted, differential cell counts were done by FACS 
analysis, as described previously [35]. Frozen lung sections 
were stained with hematoxylin / eosin for histological analysis.
Mediator measurements in BALF
ATP levels in BALF were measured using ATPLite 
kit (Perkin Elmer), as previously described [4]. BALF 
cytokine contents were determined by ELISA (R&D 
Systems, Minneapolis, USA), as described by the 
manufacturer. BALF collagen content was measured by 
Sircol assay (Biocolor, Carrickfergus, U.K.).
Collagen quantification in histological lung slides
Frozen lung sections were incubated in picrosirius 
red solution (0, 2 gr of Picosirius Red diluted in 100 ml 
of 1, 2% picric acid, both Sigma-Aldrich), for one hour. 
After washing with water, tissue sections were stained 
with hematoxylin for 5–10 seconds. Slides were washed 
with running tap water and dehydrated in 70%, 90% 
and absolute ethanol, followed by xylene. Entellan 
(Merck) was used to mount the coverslip. Images were 
obtained using Axio Lab.A1 microscope (Zeiss) with 
200 × magnification and AxioCam ICc1 (Zeiss). Collagen 
quantification was made with ImageJ.
PCR
Total RNA from human or murine lung tissue 
was isolated using RNeasy mini-kits (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
recommendations followed by reverse transcription 
using Stratascript reverse transcriptase (Stratagene, La 
Jolla, CA) and random primers (Invitrogen, Karlsruhe, 
Germany). Quantitative PCR was performed with 
Taqman Universal PCR Mastermix (Applied Biosystems, 
Figure 6: Mechanisms in P2Y2R-induced inflammation and fibrosis. (A) Wild type or P2Y2R-deficient (P2Y2R−/−) animals 
received an i. t. injection of ATP. BAL was performed after 24 h, and the number of BALF neutrophils and macrophages was determined. 
*p < 0.05 compared to ATP-treated wild type animals. (B) Primary lung fibroblasts were generated from wild type or P2Y
2
R-deficient 
animals. Migration towards ATP (100 µM) was analysed via Boyden chamber (n = 3 per group). (C) Proliferation rate of primary lung 
murine fibroblasts derived from wild type or P2Y
2
R-deficient animals (left) or human fibroblasts (right) after stimulation with ATP or UTP. 
(n = 3–5 per group). *p < 0.05 compared to vehicle stimulated cells. (D) IL6 release of primary murine lung fibroblasts (left and middle) 
or human lung fibroblasts (right) stimulated with different nucleotides was measured by ELISA (n = 3–7 per group). *p < 0.05 compared 
to vehicle-stimulated fibroblasts. 
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Foster City, CA) and pre-formulated primers and probe 
mixes (Assay on Demand; Applied Biosystems). PCR 
was performed on a thermal cycler (iCycler; Bio-Rad, 
Hercules, CA). PCR amplification of the housekeeping 
gene encoding glyceraldehyde 3-phosphate dehydrogenase 
was performed during each run for each sample to allow 
normalization between samples.
In vivo detection of extracellular ATP release 
For this imaging, 2 × 106 cells with membrane-
targeted luciferase (PME cells) were injected intravenously 
via tail vein and recipient mice were examined 
consecutively after bleomycin administration [19, 36]. 
In vitro migration of lung fibroblasts or blood 
neutrophils
Blood neutrophils from whole blood of control 
subjects or IPF patients as well as human and murine 
fibroblasts were isolated as described previously [5, 37]. 
Migration was investigated using transwell 
chambers (Corning, Lowell, USA). Nucleotides or vehicle 
were added into the lower compartment wells. Cells 
(5 × 104 cells/well) were added to the upper compartment 
and incubated at 37°C for 3 h min in a humidified 
atmosphere; cells in the lower compartment were counted. 
Results are shown as chemotactic index, calculated as 
the number of cells in the lower chamber containing the 
different stimuli divided by the number of cells in the 
chamber containing medium alone.
Proliferation of lung fibroblasts
Fibroblasts (2 × 105 cells/well) were seeded into cell 
culture plates and stimulated with the indicated nucleotides 
or vehicle. Higher concentrations of FCS (20%) were used 
as a positive control. After 48 h cells were trypsinized 
and counted. Results are shown as proliferation index, 
calculated as the number of nucleotide-stimulated cells 
divided by the number of vehicle treated cells.
Abbreviations
ATP: adenosine-5′-triphosphate; BAL: broncho-
alveolar lavage; COPD: chronic obstructive pulmonary 
disease; IL: interleukin; IPF: idiopathic pulmonary 
fibrosis; UTP: uridine-5′-triphosphate.
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